2nd Peking University Urology Academic Forum | Professor Jianye Wang: Current Priorities, Clinical Challenges, and Future Directions in Urinary Continence and Pelvic Floor Disorders

2nd Peking University Urology Academic Forum | Professor Jianye Wang: Current Priorities, Clinical Challenges, and Future Directions in Urinary Continence and Pelvic Floor Disorders

Urinary continence and pelvic floor disorders represent an important subspecialty within urology. Conditions such as post-prostatectomy urinary incontinence and overactive bladder (OAB), which are particularly common in elderly populations, can severely compromise patients’ quality of life.
Professor Kohei Shitara: Advancing Immunotherapy in Gastrointestinal Cancers—Cancer Vaccines, T-Cell Engagers, and Other Emerging Strategies May Lead the Next Wave 

Professor Kohei Shitara: Advancing Immunotherapy in Gastrointestinal Cancers—Cancer Vaccines, T-Cell Engagers, and Other Emerging Strategies May Lead the Next Wave 

 Immunotherapy has fundamentally reshaped the treatment landscape of gastrointestinal (GI) cancers. However, now that PD-1/PD-L1 inhibitors have been firmly established as standards of care, the key challenge facing clinical research is how to further overcome the current efficacy plateau. This has driven research into a “deep-water zone,” where novel strategies—such as next-generation TIGIT inhibitors, cancer vaccines, and T-cell engagers—are actively being explored.
Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

Acute promyelocytic leukemia (APL) is among the most curable forms of pediatric acute myeloid leukemia, primarily due to the success of ATRA and arsenic trioxide (ATO)-based therapies. However, the contribution of cytarabine (Ara-C) to long-term outcomes remains debated. In this newly published study in Blood Science, researchers present the results of a prospective, randomized trial examining the long-term impact of adding Ara-C during consolidation therapy for children with APL.

test

  document.getElementById("video").style.height=document.getElementById("video").scr